More than 70% of drug candidates worldwide are chiral. Typically, for chiral API, only one enantiomer or diasteromer is biologically active or desirable. Therefore, the production of enantiopure compounds or diastereomers is imperative. To produce small molecule drugs with desired chirality, chiral separation via crystallization can be much more economical and environmentally favorable than chromatography.

•  Classical Chiral Resolution 

   Classical chiral resolution of an enantiomeric acid or base via diastereomeric salt formation and crystallization is a

   common approach to separate the desired enantiomer from its racemic mixture. From screening for desired resolving 

   agent, polymorph and solvent to design and optimization of crystallization process, we offer solutions catering various

   specific needs in chiral separation.

•  Preferential Crystallization 

   The upper limit of 50% yield to an enantiopure compound by conventional chiral separation methods can be surpassed

   by combining racemization with crystallization of an enantiomer from its racemic mixture (or conglomerate). Identification

   of proper racemizing agent and implementation of crystallization engineering effectively aid our successful design and

   optimization of preferential crystallization processes.Production of Metastable Form.

Crystal Pharmatech is the first technology-driven, China based contract research organization (CRO) that focuses on materials science and engineering for drug development. We partner with clients to ensure comprehensive solutions for their needs in solid-state research, crystallization process development, and preformulation studies. We guide clients in the discovery and selection of the optimal solid phase for drug development using all aspects of pre-formulation studies, including API process and formulation development, regulatory support and intellectual property protection.

Founded in 2010, Crystal Pharmatech has business relationships with over 60 global pharmaceutical companies. High quality service, a culture of confidentiality, and fast turnaround with cost-effective pricing are our trademarks. As we continue to grow, Crystal Pharmatech will always keep customers our number one priority. We will also continue to be at the forefront of innovation in the field of solid-state chemistry so that our customers can reap the benefits of key discoveries in an ever changing field.

Our Scientific Advisory Board includes global leaders in drug development covering amorphous dispersions, co-crystals, crystallization, solid forms, formulation and pre-formulation. The role of our board is all encompassing while we search for new scientific areas for internal and external projects.